607 related articles for article (PubMed ID: 21233402)
1. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
[TBL] [Abstract][Full Text] [Related]
2. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
4. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
5. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
[TBL] [Abstract][Full Text] [Related]
6. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Dziadziuszko R; Witta SE; Cappuzzo F; Park S; Tanaka K; Danenberg PV; Barón AE; Crino L; Franklin WA; Bunn PA; Varella-Garcia M; Danenberg KD; Hirsch FR
Clin Cancer Res; 2006 May; 12(10):3078-84. PubMed ID: 16707605
[TBL] [Abstract][Full Text] [Related]
9. Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
[TBL] [Abstract][Full Text] [Related]
10. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
[TBL] [Abstract][Full Text] [Related]
14. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Costa C; Molina MA; Drozdowskyj A; Giménez-Capitán A; Bertran-Alamillo J; Karachaliou N; Gervais R; Massuti B; Wei J; Moran T; Majem M; Felip E; Carcereny E; Garcia-Campelo R; Viteri S; Taron M; Ono M; Giannikopoulos P; Bivona T; Rosell R
Clin Cancer Res; 2014 Apr; 20(7):2001-10. PubMed ID: 24493829
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
[TBL] [Abstract][Full Text] [Related]
16. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
[TBL] [Abstract][Full Text] [Related]
17. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
18. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Pietanza MC; Lynch TJ; Lara PN; Cho J; Yanagihara RH; Vrindavanam N; Chowhan NM; Gadgeel SM; Pennell NA; Funke R; Mitchell B; Wakelee HA; Miller VA
J Thorac Oncol; 2012 Jan; 7(1):219-26. PubMed ID: 22011666
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Tsao MS; Sakurada A; Cutz JC; Zhu CQ; Kamel-Reid S; Squire J; Lorimer I; Zhang T; Liu N; Daneshmand M; Marrano P; da Cunha Santos G; Lagarde A; Richardson F; Seymour L; Whitehead M; Ding K; Pater J; Shepherd FA
N Engl J Med; 2005 Jul; 353(2):133-44. PubMed ID: 16014883
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Tsuta K; Fukui T; Sakamoto H; Yoshida T; Tateishi U; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Matsuno Y; Furuta K; Tamura T
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5385-90. PubMed ID: 17875767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]